Innate Pharma (IPHYF) Debt to Equity (2017 - 2019)

Innate Pharma's Debt to Equity history spans 3 years, with the latest figure at $0.09 for Q4 2019.

  • For Q4 2019, Debt to Equity rose 153.11% year-over-year to $0.09; the TTM value through Dec 2019 reached $0.09, up 153.11%, while the annual FY2019 figure was $0.09, 153.11% up from the prior year.
  • Debt to Equity reached $0.09 in Q4 2019 per IPHYF's latest filing, up from $0.03 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.09 in Q4 2019 to a low of $0.03 in Q4 2018.
  • Average Debt to Equity over 3 years is $0.06, with a median of $0.07 recorded in 2017.
  • Peak YoY movement for Debt to Equity: crashed 50.13% in 2018, then skyrocketed 153.11% in 2019.
  • A 3-year view of Debt to Equity shows it stood at $0.07 in 2017, then plummeted by 50.13% to $0.03 in 2018, then surged by 153.11% to $0.09 in 2019.
  • Per Business Quant, the three most recent readings for IPHYF's Debt to Equity are $0.09 (Q4 2019), $0.03 (Q4 2018), and $0.07 (Q4 2017).